RegimensTaxaneDoxorubicinRegimenOutcomesHER2TumorsRecurrenceType of chemotherapyCyclophosphamideRadiotherapyMetastatic diseaseSurvivalMethodsNeoadjuvant and adjuvantCytotoxicCombination chemotherapyClinical trialsInvolving the chemotherapy drugsTherapyResponse to neoadjuvantPartial-breast irradiationCardiotoxicityCarboplatinOncologyPreoperativePathologicFluorouracilTherapiesSubgroupVersus2018Sentinel lymph nodeOvarianCardiacInvasive breastCurativeMedianLymph nodeDiagnosisConclusionsEpirubicinBevacizumabTrastuzumab basedNode-positive breast cancerConcurrentlyAggressiveIncidenceDose
Regimens19
- Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. (drugs.com)
- Eribulin was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies. (wikipedia.org)
- With the introduction of anthracycline-based regimens, 5-year survival rates have significantly improved in patients with early-stage breast cancer. (carcinogenesis.com)
- We also review the data the efficacy and safety of anthracycline-based and nonanthracycline-based adjuvant chemotherapy regimens combined with trastuzumab, and optimum chemotherapy regimens in small HER2-positive tumors. (carcinogenesis.com)
- Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer. (curehunter.com)
- A combined analysis of two trials found that trastuzumab with adjuvant chemotherapy (doxorubicin, cyclophosphamide and paclitaxel) improved the relative risk of disease-free survival by 52% (HR 0.48, 95% CI 0.39 to 0.59), compared with multiple control groups receiving different chemotherapy regimens. (nps.org.au)
- Comparisons between the trials are hampered by differences between them in the chemotherapy regimens used, the types of women included and the characteristics of their cancers. (nps.org.au)
- 85% for historical regimens (ie, cyclophosphamide/methotrexate/fluorouracil) are known to affect breast cancer survival. (jnccn.org)
- Landmark meta-analyses by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) initially showed a 20% to 25% relative risk reduction in breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. (jnccn.org)
- 1,2 Similarly, there are increased risks of congestive heart failure in adults treated with anthracycline-based chemotherapy regimens, which in current practice includes patients with breast cancer, leukemia, lymphoma, sarcoma, and other cancer types. (ajmc.com)
- Many studies have reported anthracycline-based regimens increase the benefits compared to cyclophosphamide, methotrexate, and fluorouracil combinations. (kjco.org)
- 10 ] compared the oncologic outcome of the various regimens in adjuvant CTx (cyclophosphamide, methotrexate, and fluorouracil combination, anthracycline-based regimens, taxane-anthracycline-based regimens, dose-dense taxane-anthracycline-based regimens). (kjco.org)
- In the group with 4-10 positive lymph nodes, the results showed improvement in the oncologic outcomes with taxane-anthracycline-based regimens. (kjco.org)
- In the group of more than 11 lymph nodes, the results showed improvements in the oncologic outcomes with dose-dense taxane-anthracycline based regimens. (kjco.org)
- as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. (who.int)
- The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens. (herceptin.com)
- So, taking that pilot data, we stopped the trial and we said, "Let's compare it to what standard-of-care chemotherapy regimens would be," because sometimes when you're developing drugs in that neoadjuvant space, the time that you're on it does matter, especially if you're going to go on to do a comparison study with chemo. (medscape.com)
- 8 All patients had to have received no more than 3 previous cytotoxic chemotherapy regimens for locally advanced or metastatic breast cancer. (ahdbonline.com)
- Today, anthracycline and taxane-based treatment strategies are commonly used in clinical routine, since these regimens have been shown to be superior compared to other standard chemotherapies. (justia.com)
Taxane17
- Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (drugs.com)
- We investigated whether the use of ACEI/ARBs affects the clinical outcomes of primary breast cancer patients receiving taxane and anthracycline-based neoadjuvant chemotherapy. (jcancer.org)
- This threshold, in addition to early versus late dose reductions, are poorly defined for third-generation anthracycline/taxane-based chemotherapy. (jnccn.org)
- The aim of this study is to evaluate the prognostic factors of the group who received neoadjuvant chemotherapy with a taxane-anthracycline combination regimen. (kjco.org)
- We retrospectively analyzed for locally advanced breast cancer patients who received neoadjuvant chemotherapy with adjuvant extension with taxane-anthracycline combination regimen. (kjco.org)
- In order to predict an oncologic outcome from locally advanced breast cancer patients who are treated with neoadjuvant chemotherapy with taxane-anthracycline based regimen, we can use pathologic complete response, an early response to neoadjuvant chemotherapy. (kjco.org)
- For women receiving taxane-based chemotherapy, the success rate was 66%, the same as the Dignitana trial, but for the nearly one-third receiving anthracycline-based therapy, it was, "as you would have expected, much less"-around 22%, he noted. (ascopost.com)
- There were] nearly 5000 patients, and they had the choice of an anthracycline-taxane-based chemotherapy backbone with trastuzumab or the docetaxel-carboplatin regimen with trastuzumab. (onclive.com)
- Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. (who.int)
- Unless contraindicated, patients had to have received an anthracycline and/or a taxane in the neoadjuvant, adjuvant, and/or metastatic treatment setting. (ahdbonline.com)
- Overall, 91% of patients in the talazoparib arm received previous taxane therapy, and 85% received an anthracycline. (ahdbonline.com)
- Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. (justia.com)
- The present invention relates to methods, kits and systems for predicting the benefit from inclusion of taxane in a chemotherapy regimen based on the measurements of gene expression levels in tumor samples of breast cancer patients. (justia.com)
- Although, taxanes are among the most active agents, the absolute benefit of taxane-based treatment is modest (3-5%) and has to be balanced according to serious side-effects. (justia.com)
- To reduce the number of patients suffering from side effects without a clear benefit of the therapy regimen, there is a great need for novel predictive tests to identify a group of patients that can be safely treated with conventional chemotherapy and a subgroup that has a significant benefit of taxane-based treatment. (justia.com)
- Ki67-a well-known cell proliferation marker-has been described to predict the benefit from adjuvant taxane-based treatment in the PACS01 trial (Penault-Llorca, J C O, 2008). (justia.com)
- whereas, in NeoALTTO the cut-off was 30% and the treatment regime was trastuzumab, lapatinib or their combination plus taxane only-based neoadjuvant chemotherapy. (esmo.org)
Doxorubicin10
- The recently published EORTC 62012 trial which involved 455 patients with locally advanced, unresectable or metastatic high-grade soft tissue sarcomas concluded that an intensified therapy with doxorubicin and ifosfamide is not suitable for palliation of advanced soft tissue sarcomas because of the severe side-effects and should only be used when the specific goal is tumour shrinkage ( 13 ). (spandidos-publications.com)
- Further, the utility of the first-line cytostatic doxorubicin is limited by dose-related and cumulative myocardial toxicity, especially in elderly patients with pre-existing cardiac disease ( 14 ). (spandidos-publications.com)
- 101 patients received neoadjuvant chemotherapy with docetaxel and doxorubicin, 46 patients received with epirubicin and paclitaxel. (kjco.org)
- For example, a study using human Burkitt lymphoma cells found that oxidative stress actually interferes with the ability of the chemotherapy drugs doxorubicin, cisplatin, etoposide, and cytarabine to cause cancer cell death. (pinestreetfoundation.org)
- following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see section 5.1) - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
- The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. (jamanetwork.com)
- The following combinations of chemotherapy drugs may be used for advanced breast cancer: CAF (or FAC) - cyclophosphamide, doxorubicin and 5-fluorouracil CEF (or FEC) - cyclophosphamide, epirubicin and 5-fluorouracil AC - doxorubicin and cyclophosphamide EC - … 2014-04-16 Hospice care workers provide palliative care, but palliative care can be given at any time during an illness, not just at the end of life. (web.app)
- As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. (kanjinti.com)
- The main purpose of this study is to learn if adding bevacizumab to standard treatment with chemotherapy (docetaxel, doxorubicin, and cyclophosphamide) for early stage HER2-negative breast cancer will prevent breast cancer from returning. (outcomes4me.com)
- DOXOrubicin is an anthracycline. (medscape.com)
Regimen8
- Women with an especially deadly type of breast cancer who received a treatment regimen containing an experimental AbbVie Inc drug prior to surgery are likely to have a significantly better response than those who get a standard chemotherapy regimen, according to data from a clinical trial. (khaleejtimes.com)
- Patients with so-called triple negative breast cancer, who tend to be younger and have a very poor prognosis, appeared to have double the response rate to the regimen containing AbbVie's veliparib in a new type of study that exploits advances in molecular understanding of the disease, researchers found. (khaleejtimes.com)
- Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (drugs.com)
- In a Phase II study, MD Anderson researchers showed that a regimen of neoadjuvant and adjuvant treatment with checkpoint inhibitors nivolumab, a PD-1 inhibitor, and relatlimab, a LAG-3 inhibitor, was safe and effective in patients with resectable clinical stage III melanoma. (mdanderson.org)
- For many cancers, including breast cancer and lymphoma, chest radiation remains an important component of the treatment regimen. (ajmc.com)
- After curative surgery, adjuvant chemotherapy with the same regimen was performed. (kjco.org)
- The adjuvant chemotherapy regimen was adjusted when the response to neoadjuvant chemotherapy was in disease progression. (kjco.org)
- The B-46-I/07132 study, a multicenter, open-label, randomized Phase III, adjuvant therapy trial, will compare the value of adding bevacizumab to a non-anthracycline-based chemotherapy regimen relative to the same chemotherapy without bevacizumab and relative to an anthracycline-based chemotherapy regimen in women with resected node-positive or high-risk node-negative, HER2-negative breast cancer. (outcomes4me.com)
Outcomes22
- Chae YK, Brown EN, Lei X, Melhem-Bertrandt A, Giordano SH, Litton JK, Hortobagyi GN, Gonzalez-Angulo AM, Chavez-MacGregor M. Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes. (jcancer.org)
- No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy. (jcancer.org)
- Then, pertuzumab in 2012 and ado-trastuzumab emtansine in 2013 were approved in the US and elsewhere based on evidence showing an improvement in survival outcomes in patients with mostly trastuzumab naïve or trastuzumab-exposed metastatic disease. (carcinogenesis.com)
- [1] Although chemotherapy has improved outcomes for patients, the marginal benefits achieved with cytotoxic agents seem to have reached a plateau. (carcinogenesis.com)
- Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). (curehunter.com)
- Published in the J ournal of the American College of Cardiology , the "Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes" (SUCCOUR) randomized controlled trial did not meet its primary outcome, as there was no difference in the continuous measure of heart function for all patients in the LVEF-guided and GLS-guided arms in both treated and untreated patients. (newswise.com)
- In patients with breast cancer receiving adjuvant 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel (FEC-D), we evaluated the impact of chemotherapy total cumulative dose (TCD), and early (FEC) versus late (D only) dose reductions, on survival outcomes. (jnccn.org)
- Conversely, early reductions (FEC±D) negatively affected patient outcomes. (jnccn.org)
- Comparative real-world outcomes for patients with HER2-positive (HER2+) breast cancer receiving adjuvant trastuzumab outside of clinical trials are lacking. (jnccn.org)
- This study sought to retrospectively characterize outcomes for patients with node-negative and node-positive breast cancer receiving adjuvant trastuzumab in combination with docetaxel/cyclophosphamide (DCH), docetaxel/carboplatin/trastuzumab (TCH), or fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (FEC-DH) chemotherapy in Alberta, Canada, from 2007 through 2014. (jnccn.org)
- The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting , highlight new advances in drug therapy research to improve patient outcomes. (mdanderson.org)
- Amaria and other researchers are continuing to follow patient outcomes and will be conducting further translational studies to discern the mechanisms of response and resistance to this combination. (mdanderson.org)
- With the prognosis for many cancers improving, we are seeing an appropriate sharpening of focus on the cardiovascular risks of patients who have survived cancer or are being treated for cancer, as well as a growing recognition of the impact this competing morbidity has on both short- and long-term health outcomes. (ajmc.com)
- The MGH Cardio-Oncology Program introduced in 2011 is a joint initiative between the Heart and Cancer Centers at Massachusetts General Hospital that provides comprehensive cardiovascular care to cancer patients, with the goal of improving short- and long-term outcomes ( Figure ). (ajmc.com)
- For many patients, determining if there are cardiovascular risks that need to be addressed before they undergo medical or surgical treatments for cancer is necessary in order to ensure optimal outcomes. (ajmc.com)
- Background: Adverse outcomes in breast cancer patients treated with recombinant human erythropoietin (rhEpo) have been linked to the expression of Epo-receptors (EpoR) in cancer cells, although limited data on the clinical significance of these observations are available. (iiarjournals.org)
- Many studies have reported that there are no differences in the oncologic outcomes between NC and adjuvant chemotherapy [ 2 ]. (kjco.org)
- The taxanes have been used to improve treatment outcomes alone or with anthracycline [ 7 - 9 ]. (kjco.org)
- This is based on data coming from the Netherlands looking at a prospective cohort of patients, [where the] T1b patients receiving trastuzumab have better outcomes. (onclive.com)
- If you look at long-term outcomes from HER2-positive patients in the adjuvant setting, and you were to compare the ER-positive versus ER-negative patients, you can see that their long-term outcomes are not that dissimilar. (targetedonc.com)
- A multidisciplinary team approach involving cardiology, medical oncology, nursing, social work, rehab and pharmacology improves cardiac outcomes for cancer patients. (ottawaheart.ca)
- These opportunities are a great way to contribute to the literature while reinforcing our ever-present, all-important goal: strengthening patient outcomes in radiation oncology. (appliedradiationoncology.com)
HER238
- Triple-negative tumors - about 15 per cent of breast cancers - lack estrogen, progesterone or HER2 receptors needed for most drugs to work. (khaleejtimes.com)
- Trastuzumab (Herceptin) has been lauded as a breakthrough treatment for HER2-positive breast cancer, an especially aggressive type of cancer. (acc.org)
- With the addition of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), improvements in overall survival have been observed among patients with advanced HER2-positive disease. (carcinogenesis.com)
- Subsequently, lapatinib, an orally bioavailable small molecule dual HER2- and EGFR/HER1-specific tyrosine kinase inhibitor, received Food and Drug Administration (FDA) approval in combination with capecitabine for patients with advanced HER2+ breast cancer. (carcinogenesis.com)
- The FDA also approved 1 year of extended adjuvant neratinib after chemotherapy and a year of trastuzumab for HER2-positive breast cancer on the basis of the ExteNET trial. (carcinogenesis.com)
- The clinical benefit demonstrated by those drugs in advanced disease has triggered several adjuvant and neoadjuvant trials testing them in combination with chemotherapy, but also without conventional chemotherapy, using single or dual HER2-targeting drugs. (carcinogenesis.com)
- In this article, we review the current data on the therapeutic management of HER2-positive early-stage breast cancer in the adjuvant and neoadjuvant setting. (carcinogenesis.com)
- One type of breast cancer is identified by the human epidermal growth factor receptor 2 (HER2) gene amplification. (carcinogenesis.com)
- This subtype accounts for approximately 20%-30% of invasive breast cancers, and until the discovery of effective anti-HER2 therapies ( first of which is trastuzumab), was associated with reduced disease-free survival (DFS), increased risk of metastases, and shorter overall survival (OS). (carcinogenesis.com)
- Over-expression (excess production of protein) or amplification (an excess number of gene copies) of the HER2 gene is associated with aggressive behaviour in affected cancer cells 1 , and occurs in 15-30% of breast cancers. (nps.org.au)
- Trastuzumab is listed on the Pharmaceutical Benefits Scheme (PBS) as an authority prescription for the initial and continuing treatment of HER2-positive early breast cancer, starting concurrently with adjuvant chemotherapy after surgical excision. (nps.org.au)
- The primary trial of trastuzumab in early breast cancer is the HERA trial, conducted in 5081 women with cancers showing HER2 amplification or HER2 overexpression. (nps.org.au)
- Women with stage I-III, hormone receptor-positive/negative, HER2-negative breast cancer treated with adjuvant FEC-D chemotherapy from 2007 through 2014 in Alberta, Canada, were included. (jnccn.org)
- Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. (mdanderson.org)
- In a nonrandomized, open-label Phase II study, MD Anderson researchers demonstrated that talazoparib, a PARP inhibitor, showed activity in patients with germline BRCA1/2 mutation-positive, early HER2-negative breast cancer. (mdanderson.org)
- Learn about Herceptin's legacy of treating HER2-positive metastatic breast cancer. (herceptin.com)
- Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease. (herceptin.com)
- Pfizer), an oral PARP inhibitor, for the treatment of adults with deleterious or suspected deleterious germline BRCA mutation-positive, HER2 -negative -locally advanced or metastatic breast cancer. (ahdbonline.com)
- 8 In this open-label study, 431 patients with germline BRCA mutation-positive, HER2 -negative locally advanced or metastatic breast cancer were randomized to talazoparib 1 mg once daily (N = 287) or to the physician's choice of single-agent chemotherapy with capecitabine, eribulin, gemcitabine, or vinorelbine (N = 144). (ahdbonline.com)
- The most challenging treatment decision in this context concerns ER+/HER2-breast cancer patients, for which classical clinical factors like grading, tumor size or lymph node involvement do not provide a clear answer to the question whether to use chemotherapy or not and what type of treatment therapy is appropriate for the individual patient. (justia.com)
- During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer. (targetedonc.com)
- ER-positive, HER2-positive patients tend to do slightly better. (targetedonc.com)
- You'll see that ER-positive, HER2- positive cancers tend to have recurrences a bit later than the ER-negative, HER2-positive cancers. (targetedonc.com)
- But we do know that in a preoperative setting that the ER-positive, HER2-positive patients do have a lower likelihood of achieving pCR [pathologic complete response] to preoperative therapy, even though. (targetedonc.com)
- I find it hard to know what to do for that patient because if they ended up having, [for example], 1.2-cm HER2-positive cancer that was node negative, you take them straight to surgery and they could get away with just TH [paclitaxel, trastuzumab]. (targetedonc.com)
- Baseline levels of tumour infiltrating lymphocytes (TIL) in pre-treatment biopsies from patients with HER2-positive breast cancer are significantly associated with pathological complete response (pCR) rates following neoadjuvant chemotherapy plus anti-HER2 agents (trastuzumab, lapatinib or their combination). (esmo.org)
- Cinzia Solinas of the Institut Jules Bordet, Bruxelles, Belgium and colleagues performed a systematic search of the PubMed, Embase and Cochrane library databases for randomised controlled trials (RCT) investigating neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination in HER2-positive breast cancer up until 31 October, 2016. (esmo.org)
- No interaction was observed between high versus non-high TIL subgroups in terms of response to anti-HER2 agents, trastuzumab versus lapatinib versus trastuzumab/lapatinib (p = 0.747) or between regimes containing anthracyclines plus taxanes versus taxanes alone (p = 0.201). (esmo.org)
- The authors noted that in HER2-positive breast cancer, high baseline TIL are associated with increased pCR probability, irrespective of anti-HER2 agent(s) and neoadjuvant chemotherapy regimes used. (esmo.org)
- 60% TIL prior to treatment demonstrated a stronger benefit from neoadjuvant chemotherapy combined with anti-HER2 therapy. (esmo.org)
- KANJINTI® is used for the treatment of early … Read more -stage breast cancer that is H uman E pidermal growth factor R eceptor 2 -positive … Read more ( HER2 +) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. (kanjinti.com)
- KANJINTI® is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease. (kanjinti.com)
- What is her2-positive (HER2+) cancer? (kanjinti.com)
- If there are a large number of HER2 proteins, the cancer is said to be HER2+. (kanjinti.com)
- A second purpose of this study is to learn if adding bevacizumab to treatment with chemotherapy will help women with HER2-negative breast cancer live longer. (outcomes4me.com)
- the breast cancer must be her2-negative based on current american society of clinical oncology (asco)/college of american pathologists (cap) guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. (outcomes4me.com)
- if the result of the in situ hybridization testing (fish, chromagen in situ hybridization (cish), or other) is equivocal, the patient is eligible if there is no plan to administer her2-targeted therapy. (outcomes4me.com)
- Herzuma (trastuzumab-pkrb) is a HER2 /neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer . (rxlist.com)
Tumors12
- Most breast cancer tumors are estrogen-receptor positive, fueled by the hormone estrogen. (khaleejtimes.com)
- Samples of adrenal tumors were collected from patients undergoing adrenalectomy at the Department of Urology, the First Hospital of China Medical University. (cancerindex.org)
- It has been said that African patients present late with aggressive tumors and face a lack of therapeutic options, resulting in short survival duration. (karger.com)
- Assuming a patient hasn't received neoadjuvant therapy and they're coming in after surgery, the NCCN Guidelines are relatively vague as to whether to give trastuzumab-based chemotherapy in small tumors. (onclive.com)
- 4 The other 2 PARP inhibitors approved by the FDA, rucaparib (Rubraca) and niraparib (Zejula), are approved for other types of tumors but not for breast cancer. (ahdbonline.com)
- The primary efficacy end point was progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors and a blinded independent review. (ahdbonline.com)
- PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. (bvsalud.org)
- OncotypeDX can help decisions in patients with tumors between 1 and 2 cm. (medscape.com)
- Palliative chemotherapy for patients with breast cancer In recent years, the survival of women with metastatic breast cancer has improved substantially thanks to 2019-05-20 · Background The benefit of palliative chemotherapy (PC) in patients with advanced solid tumors and poor performance status (ECOG-PS) has not been prospectively validated, which makes treatment decision challenging. (web.app)
- Given the ever increasing understanding of molecular targets, of the drivers of disease progression, and the heterogeneity of human malignancy, which has ushered in the era of targeted treatment, the reality of the patient with cancer has Most often neo-adjuvant chemotherapy will be used on breast cancer patients with tumors greater than 2 cm in size and where the cancer has not spread to other parts of the body. (web.app)
- Adenocarcinoma cancers being usually in one of the following organs: prostate, breast, colon, When cancerous tumors form on connective tissues, it is a sarcoma. (web.app)
- Patients will also receive adjuvant radiation therapy as clinically indicated and endocrine therapy for hormone receptor-positive tumors. (outcomes4me.com)
Recurrence9
- If the tumor does not respond to chemotherapy, there are currently no alternatives and the typical survival rate after recurrence is less than two years. (khaleejtimes.com)
- Furthermore, these three genes predicted overall survival and recurrence‑free survival in patients with ACC from the TCGA cohort. (cancerindex.org)
- Patients with increased EpoR-mRNA expression had a higher local cancer recurrence rate (p=0.021), however, no significant difference in overall survival was observed. (iiarjournals.org)
- After surgical removal of the primary tumor, breast cancer patients are frequently treated with radiotherapy, hormone therapy and cytotoxic chemotherapy to reduce the risk of recurrence. (justia.com)
- And so, certainly prior to the advent of trastuzumab [Herceptin], this patient would have a high risk of recurrence. (targetedonc.com)
- Only one patient experienced a locoregional recurrence with synchronous distant progression, and subsequently succumbed to the disease. (researchwithrutgers.com)
- Present data do not support the use of CA 15-3 and CA 27.29 for monitoring patients for recurrence after primary breast cancer therapy. (medscape.com)
- Adjuvant polychemotherapy (e.g. with 58% to 68%) for patients under the age of 50.1 Besides an cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) or improvement in clinical outcome, these figures indicate that anthracycline-containing regimes, produce substantial reduc- a large proportion of the patients will never recur after the tion in recurrence and mortality. (lu.se)
- Possible mechanisms for gram for breast cancer in southern Sweden issued 1991, pre- recurrence after treatment are low initial drug sensitivity or menopausal lymph node positive (N+) breast cancer patients an acquired drug resistance. (lu.se)
Type of chemotherapy2
- Our data affirm that anthracyclines are aggressive agents that can cause damage to the heart muscle on a much greater scale than trastuzumab," she said, adding that the damage may already be done from prior exposure to this type of chemotherapy. (acc.org)
- Decades of data allow clinicians to "set expectations" for hair preservation based on the type of chemotherapy a patient is receiving. (ascopost.com)
Cyclophosphamide2
- In the Dignitana trial, 3 among 101 women with stage I or II breast cancer who used scalp cooling and 16 who did not, the overall rate of success (defined as 50% or greater hair retention 4 weeks after completion of treatment) was 66% in a cohort of primarily docetaxel-plus-cyclophosphamide recipients. (ascopost.com)
- and Group 3 patients will receive 6 cycles of TCB every 21 days with bevacizumab therapy continuing every 21 days after completion of chemotherapy until 1 year following the first dose (docetaxel 75 mg/m2, cyclophosphamide 600 mg/m2, and bevacizumab 15 mg/kg). (outcomes4me.com)
Radiotherapy4
- All patients received radiotherapy, adjuvant anthracycline-based chemotherapy and five years of tamoxifen treatment. (biomedcentral.com)
- Radiotherapy, including internal mammary nodal irradiation, and heart failure in patients receiving concurrent treatment with trastuzumab further explores the critical challenge of RT-induced cardiotoxicity. (appliedradiationoncology.com)
- A deep learning framework was constructed to predict patient survival probabilities and competing risk types at discrete time points, given the pseudo values and patient covariants including: age, deprivation (SIMD), co-morbidity (Charlson), year of diagnosis, side of radiotherapy, cancer stage, grade, ER & HER 2 status. (ed.ac.uk)
- Radiotherapy was delivered to ipsilateral axil- cancer patients in the future, it is essential to increase our lary and supraclavicular lymph nodes and the remaining knowledge in mechanisms responsible for drug resistance, breast parenchyma after breast conservation surgery or tho- and to define reliable indicators for response to therapy. (lu.se)
Metastatic disease2
- Biocon Biologics Ltd), BT-ON014 - in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease - in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab. (who.int)
- For monitoring patients with metastatic disease during active therapy, CA 15-3 or CA 27.29 can be used in conjunction with diagnostic imaging, history, and physical examination. (medscape.com)
Survival13
- Advances in screening and treatment have improved survival for U.S. women with breast cancer. (cdc.gov)
- If we can increase the number of patients who have no invasive cancer, we expect that this will translate into better survival," Rugo said. (khaleejtimes.com)
- Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. (curehunter.com)
- 85% for adjuvant FEC-D affects breast cancer survival. (jnccn.org)
- Treatment of early-stage breast cancer with adjuvant chemotherapy has improved survival. (jnccn.org)
- Disease-free survival and overall survival (OS) analyses for node-negative cohorts receiving DCH (n=111) or TCH (n=371) and node-positive cohorts receiving FEC-DH (n=146) or TCH (n=315) were compared using chi-square, Kaplan-Meier, or Cox multivariable analysis where appropriate. (jnccn.org)
- Recently, clinical trials involving anaemic and non-anaemic cancer patients have raised questions concerning the safety of ESAs with respect to survival ( 11 , 12 ) and promotion of thrombembolic events ( 13 - 15 ). (iiarjournals.org)
- One example is a human study in which researchers discovered that higher levels of the antioxidant selenium in the blood of patients with aggressive B-cell non-Hodgkin's lymphoma correlated with increased achievable doses of anthracycline based chemotherapy, better treatment response, achievement of long term remission, and longer overall survival. (pinestreetfoundation.org)
- 5 "The increased survival in breast cancer to unprecedented levels in the past few decades has now resulted in patients being able to focus on the psychosocial consequences of their treatment. (ascopost.com)
- These findings indicate that high PAI-1 mRNA expression represents a strong and independent unfavorable prognostic factor for the development of metastases and for breast cancer specific survival in a population of hormone receptor- and lymph node-positive breast cancer patients. (biomedcentral.com)
- The four-year follow-up data is part of the ongoing follow-up study to assess cardiac safety and survival outcome in a subgroup of patients from the Phase 3 study who completed neoadjuvant and adjuvant therapy for one year. (biospace.com)
- The cause-specific cumulative incidence function was used to calculate pseudo survival probabilities for the primary outcome, and the competing risks of death from breast cancer and death from other causes. (ed.ac.uk)
- Breast cancer is a heterogeneous disease with a large variabil- survival after adjuvant polychemotherapy was 10% (from ity in clinical outcome. (lu.se)
Methods8
- Patients and Methods: Tissue samples from 107 patients with breast cancer who did not receive rhEpo and from 12 patients with benign lesions were retrospectively analysed for EpoR expression by RT-PCR and Western blot, and the results were correlated to clinical and demographic data. (iiarjournals.org)
- Methods: From April 2010 to 2018, 104 patients were included. (bvsalud.org)
- METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. (bvsalud.org)
- Methods and Materials: We analyzed all patients treated at our institution with bilateral RNI using VMAT between 2017 and 2020. (researchwithrutgers.com)
- The cover article, Cardiac-sparing radiation therapy for breast cancer, examines the wide variety of methods for adjuvant breast or chest wall RT that can help minimize radiation dose to the heart-a key contributor to coronary stenosis and other cardiac diseases. (appliedradiationoncology.com)
- Methods: Patients treated surgically for stage I-III invasive breast cancer between 2000 & 2016 were identified from in the Scottish Cancer Registry. (ed.ac.uk)
- The comparable results found with traditional methods in this study is consequence of the reliance on base-line covariants. (ed.ac.uk)
- Patients and methods proportion of the patients will recur despite treatment with adjuvant polychemotherapy. (lu.se)
Neoadjuvant and adjuvant1
- Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors. (curehunter.com)
Cytotoxic1
- BT-ON014 trade name] treatment should only be initiated by a health care provider experienced in the administration of cytotoxic chemotherapy (see section 4.4), and should be administered by a health care provider only. (who.int)
Combination chemotherapy1
Clinical trials10
- This type of trial should help companies select the right group of patients to enroll into larger, more traditional late stage clinical trials, potentially cutting the cost of bringing new medicines to market. (khaleejtimes.com)
- If a drug combination starts to look like it is working better on patients with one type of breast cancer, the trial design allows for more patients with that type of cancer to move into that arm of the study, said Rugo, director of breast oncology and clinical trials education at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco. (khaleejtimes.com)
- We suggest that current information regarding the structure, mechanism and regulation of ABC transporters should be used in clinical trials to improve the efficiency of chemotherapeutics for patients with cancer. (nature.com)
- As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. (mdanderson.org)
- Several large clinical trials demonstrated that the addition of taxanes to anthracycline-based treatment strategies results in an improved clinical outcome (Martin et al. (justia.com)
- These data, based on a meta-analysis of published data from five large clinical trials, will be reported at the IMPAKT Breast Cancer Conference in Brussels, Belgium on 4 to 6 May 2017. (esmo.org)
- breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. (web.app)
- We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. (biomedcentral.com)
- At present, several antiangiogenic therapies are in clinical trials testing their promise in breast cancer. (biomedcentral.com)
- Background: Clinical trials have demonstrated that anthracycline chemotherapy for the adjuvant treatment of early breast cancer (EBC) reduces breast cancer mortality but increases cardiac risk. (ed.ac.uk)
Involving the chemotherapy drugs1
- 2000) A second study, involving the chemotherapy drugs etoposide and calcimycin, confirms this finding: Human Burkitt's lymphoma cells were unable to die quickly by apoptosis in the presence of oxidative stress and instead died using the slower and messier method of necrosis. (pinestreetfoundation.org)
Therapy43
- Breast cancer patients who started taking one of two well-known heart medications at the same time they initiated trastuzumab-a targeted cancer therapy that has been linked to heart damage-received no benefit in terms of preventing declines in heart function, according to research presented at the American College of Cardiology's 67th Annual Scientific Session. (acc.org)
- However, Guglin said some studies have shown that up to 1 in 4 women who receive this therapy experience cardiac effects, including symptomatic heart failure, a condition in which the heart becomes too weak to pump enough blood to meet the body's needs. (acc.org)
- Guglin explained that while anthracycline chemotherapy can cause long-lasting, potentially irreversible damage to the heart muscle, trastuzumab therapy has been associated with milder and often temporary declines in cardiac function. (acc.org)
- Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. (curehunter.com)
- 6 Trastuzumab therapy for 1-2 years after excision and adjuvant chemotherapy was compared with excision and adjuvant chemotherapy alone. (nps.org.au)
- However, what's of clinical importance are the patients who se abnormal change in heart function resulted in the initiation of therapy. (newswise.com)
- When a change in measurement alerted Dr. Thavendiranathan that the cancer therapy was damaging her heart, he initiated cardio-protective therapy - drugs that help improve heart function and prevent further damage. (newswise.com)
- Our findings suggest we should consider changing how we follow patients during cancer therapy and add GLS to routine heart surveillance," says Dr. Thavendiranathan , who co-led the study at 28 centres with Dr. Thomas Marwick of the Baker Heart and Diabetes Institute , and Dr. Tomoko Negishi of the Menzies Research Institute. (newswise.com)
- Thirty patients were enrolled in the study and received two doses of nivolumab with relatlimab before surgery, followed by up to 10 additional doses of the combination therapy after surgery. (mdanderson.org)
- There are data suggesting that early recognition of chemotherapy-induced cardiomyopathy and prompt initiation of medical therapy can promote recovery of cardiac function. (ajmc.com)
- Working closely with the cancer care team, we provide a comprehensive cardiovascular evaluation and treatment plan prior to cancer therapy to minimize cardiovascular complications. (ajmc.com)
- Neoadjuvant chemotherapy (NC) is a standard therapy for locally advanced breast cancer patients [ 1 ]. (kjco.org)
- Success rates with anthracycline therapy are lower but certainly better than if you do nothing, which yields a 100% failure rate. (ascopost.com)
- Virginia G. Kaklamani, MD, DSc, and Melinda L. Telli, MD, review the various adjuvant therapy options available for patients with HER2+ early breast cancer based on stage, risk status, and whether or not they had received neoadjuvant therapy, and then touch on clinical data supporting the use of fixed-dose pertuzumab/trastuzumab (PH) in this setting. (onclive.com)
- 2 cm in diameter, as adjuvant therapy following neoadjuvant chemotherapy and surgery (see sections 4.4 and 5.1). (who.int)
- We were giving it for 2 months, and it was based on data from our mutual colleague and friend, Dr Mariana Chavez Mac Gregor, on what was the amount of time that you could delay starting systemic therapy. (medscape.com)
- Purpose: The traditional shrinkage classification modes might not suitable for guiding breast conserving surgery (BCS) after neoadjuvant therapy (NAT). (bvsalud.org)
- Lay abstract The purpose of this study was to integrate more pretreatment indicators, including clinicopathological factors and simple laboratory indicators, to predict axillary nodal pathologic complete response (apCR) after neoadjuvant therapy for breast cancer. (bvsalud.org)
- I think knowing that there is lymph node involvement is prompting people to use pertuzumab-based therapy. (targetedonc.com)
- So, the question [is:] do you want to give anthracycline-based therapy versus nonanthracycline-based treatment? (targetedonc.com)
- Given some newer data, I [tend] to now use nonanthracycline- based therapy for the vast majority of my patients since I have been using TCHP. (targetedonc.com)
- Would you recommend neoadjuvant systemic therapy for such patients? (targetedonc.com)
- It does put you at risk potentially for finding [a patient with] stage II disease, which is problematic, because I would have wanted to give them preoperative therapy. (targetedonc.com)
- Purpose: Dosimetric and technical challenges often limit radiation therapy (RT) target coverage for patients with breast cancer who require bilateral breast/chest wall and regional nodal irradiation (RNI). (researchwithrutgers.com)
- No patient received glucocorticoid therapy or required respiratory intervention, and none developed longer-term pulmonary complaints. (researchwithrutgers.com)
- Dr. Dent, co-founder of the Ottawa Cardiology-Oncology Clinic at The Ottawa Hospital, led the session presenting the Canada Cardiovascular Society's (CCS) first position statement on cardiovascular complications of cancer therapy (expected release in December 2015). (ottawaheart.ca)
- Having cardiovascular risk factors makes the likelihood of developing heart disease due to cancer therapy more likely. (ottawaheart.ca)
- The CCS statement recommends that routine cardiovascular evaluation should be part of care before, during and after cancer treatment, and all patients receiving cardiotoxic therapy should be considered to be at high risk for heart failure (stage A). While standard drugs to prevent and manage heart disease can reduce the risk of cardiotoxicity, up to one third of cancer patients may not tolerate these therapies. (ottawaheart.ca)
- Currently, the function of the left ventricle (LV) of the heart is the common measure of cardiac damage due to cancer therapy. (ottawaheart.ca)
- Nevertheless, in metastatic breast cancer, retrospective studies showed that elevated uPA or PAI-1 present in the primary tumor are associated with a poor response to later palliative endocrine therapy [ 14 ] suggesting that high levels of uPA and/or PAI-1 do reflect an aggressive phenotype that may be overcome by early systemic therapy in the adjuvant setting but not by palliative therapy at a later stage of the disease. (biomedcentral.com)
- Breast medical oncologists use the information provided by pathologists to make decisions about systemic therapy. (medscape.com)
- The image below provides an example of a schematic representation of a decision tree used by medical oncologists when deciding whether to administer systemic therapy and/or which systemic therapy to recommend to a patient. (medscape.com)
- Remember that the decision to give a specific systemic therapy to an individual patient is based on the expected benefit as compared with the possible risks in each individual patient. (medscape.com)
- CEA is not recommended for screening, diagnosis, staging, or routine surveillance of breast cancer after primary therapy. (medscape.com)
- First line therapy for 2001-01-01 As an oncologist, I believe the administration of chemotherapy in patients living with active cancer is not out of place with the goals of palliative care. (web.app)
- Surgery, radiation, and hormone therapy are common treatments for breast cancer. (web.app)
- Patients are selected for therapy based on an FDA-approved test for trastuzumab. (kanjinti.com)
- Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria. (biomedcentral.com)
- As a prelude to Breast Cancer Awareness Month coming up in October, we are pleased to focus this issue on several evolving areas of breast radiation therapy. (appliedradiationoncology.com)
- This definitive review assesses applicator-based brachytherapy and its toxicity-related concerns, external-beam approaches, proton therapy, intraoperative radiation therapy, and the future outlook of APBI. (appliedradiationoncology.com)
- Finally in our breast cancer lineup, we present Soft tissue sarcoma of the breast following breast-conserving therapy, a helpful case report describing the challenge of re-irradiating the left chest while managing heart and lung dose. (appliedradiationoncology.com)
- Also, it was reported that music therapy improved heart rate variability in anthracycline-treated breast cancer patients. (bvsalud.org)
- Treatment is curative in most cases and consists of chemotherapy with or without other treatment modalities, including antibody-drug conjugates, immunotherapy, and radiation therapy. (msdmanuals.com)
Response to neoadjuvant1
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. (curehunter.com)
Partial-breast irradiation1
- In Accelerated partial-breast irradiation (APBI): An emerging standard of care, Cleveland Clinic authors evaluate data supporting this underused, yet proven, technique for women with early stage breast cancer who have undergone breast-conserving surgery. (appliedradiationoncology.com)
Cardiotoxicity9
- While smaller studies have looked at the utility of these commonly-used heart medications in guarding against anthracycline-induced cardiotoxicity, this trial is one of the first and the largest to date to test whether these drugs can prevent trastuzumab-related heart damage and prevent the need to discontinue a potentially life-saving treatment. (acc.org)
- The one-year results of the highly anticipated trial compared heart function at the end of anthracycline-based chemotherapy, a treatment that can successfully treat cancer but also damage the heart, known as cardiotoxicity. (newswise.com)
- For oncologists and cardiologists, one of the primary concern s is how to prevent the development of cardiotoxicity in patients. (newswise.com)
- Prompt recognition and management of cardiotoxicity during chemotherapy is critical in order to ensure that patients can continue to receive these important treatments. (ajmc.com)
- The development of cardiotoxicity may also increase the risk of morbidity and mortality, as evidenced in an analysis of Medicare patients undergoing treatment for breast cancer. (ajmc.com)
- The position statement optimizes care for patients with cardiovascular disease or who are at risk of cardiotoxicity. (ottawaheart.ca)
- The CCS statement identifies cardiotoxicity information by cancer drug type. (ottawaheart.ca)
- For patients at risk of cardiotoxicity, good communication between the oncologist, cardiologist and family physician is essential. (ottawaheart.ca)
- The second leading cause of death for breast cancer patients is cardiotoxicity from anthracycline chemotherapy. (ottawaheart.ca)
Carboplatin2
- They found an estimated PCR in 52 per cent of women who were treated with AbbVie's veliparib plus the chemotherapies carboplatin and paclitaxel. (khaleejtimes.com)
- With the chemotherapy drugs docetaxel and carboplatin. (kanjinti.com)
Oncology8
- Department of Breast Medical Oncology, 3. (jcancer.org)
- The old standard of care was that stage III melanoma patients get surgery first, but we've shown they can really benefit from a neoadjuvant approach," said Rodabe Amaria, M.D. , associate professor of Melanoma Medical Oncology , who will present the findings. (mdanderson.org)
- Cardio-oncology, or onco-cardiology, is the discipline that focuses on the intersection of cardiovascular disease and cancer. (ajmc.com)
- Prevalence, demographics, and psychological associations of sleep disruption in patients with cancer: University of Rochester Cancer Center-Community Clinical Oncology Program. (cancer.gov)
- The majority (approximately 98%) of patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. (ahdbonline.com)
- In 2007, the American Society of Clinical Oncology (ASCO) updated their recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer. (medscape.com)
- Proceedings from conferences of the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (2005 to 2009), and the San Antonio Breast Cancer Symposium (2005 to 2009) were searched for relevant abstracts. (biomedcentral.com)
- the patient must have an eastern cooperative oncology group (ecog) performance status of 0 or 1. (outcomes4me.com)
Preoperative6
- This was an interesting story in breast cancer because the drug got approved about 10 years ago in the preoperative setting. (onclive.com)
- Initially we started with this being a 2-month pilot study where we gave 2 months of talazoparib, and then patients went on to get standard-of-care preoperative neoadjuvant chemotherapy. (medscape.com)
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. (jamanetwork.com)
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. (jamanetwork.com)
- Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. (jamanetwork.com)
- There is a preoperative trial through the [National Cancer Institute], the CompassHER2- pCR study [NCT04266249], which is looking at preoperative THP. (targetedonc.com)
Pathologic7
- SEER Summary Stage 2000 † was used to characterize cancers as localized, regional, distant, or unknown stage using clinical and pathologic tumor characteristics such as tumor size, depth of invasion and extension to regional or distant tissues, involvement of regional lymph nodes, and distant metastases. (cdc.gov)
- In that arm of the study involving 71 high risk patients, the researchers were testing to see whether the treatment, given before surgery, could eliminate any evidence of invasive cancer in breast tissue and lymph nodes removed during subsequent surgery - a measurement known as pathologic complete response (PCR). (khaleejtimes.com)
- It was an accelerated approval based on phase 2 trials showing increase in the rate of pCR [pathologic complete response] with the addition of pertuzumab to chemotherapy and trastuzumab. (onclive.com)
- We did have a few patients in which the tumor grew during that time, but what we saw is that 10 of those patients had a complete pathologic response without any chemotherapy whatsoever. (medscape.com)
- And it was really the first time that we showed that in patients with TNBC to get a pathologic complete response (pCR) in the absence of chemotherapy. (medscape.com)
- The DSS was determined based on presenting clinical stage (A), final pathologic stage (B), CPS+EG staging system (clinical-pathologic scoring system incorporating estrogen receptor-negative disease and nuclear grade 3 tumor pathology) (C), 16 - 18 and Neo-Bioscore, which includes ERBB2 status (D). (jamanetwork.com)
- The DSS was determined based on presenting clinical stage (A), final pathologic stage (B), CPS+EG staging system (clinical-pathologic scoring system incorporating ER-negative disease and nuclear grade 3 tumor pathology) (C), 16 - 18 and Neo-Bioscore, which includes ERBB2 status (D). For these analyses, patients treated prior to 2010 were considered ER positive at an ER value of 10% or higher. (jamanetwork.com)
Fluorouracil1
- For fluorouracil: Patients with dihydropyrimidine dehydrogenase (DPD) deficiency are unable to metabolize fluorouracil normally and may have severe unexpected toxicity to fluorouracil. (medscape.com)
Therapies3
- This study comes amid growing awareness that certain cancer therapies can contribute to heart failure or other heart problems. (acc.org)
- High-resolution structures, biophysical and in silico studies have led to tremendous progress in understanding the mechanism of drug transport by these ABC transporters, and several promising therapies, including irradiation-based immune and thermal therapies, and nanomedicine have been used to overcome ABC transporter-mediated cancer chemoresistance. (nature.com)
- Unfortunately , for 1 in 20 high-risk patients, treating cancer with certain therapies means the added potential of developing heart failure. (newswise.com)
Subgroup1
- 51of this subgroup of patients did not finish treatment. (bvsalud.org)
Versus3
- In these patients, the use of GLS-monitoring led to a lower reduction in heart function versus traditional monitoring. (newswise.com)
- Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. (jamanetwork.com)
- Nearly half (45.3%) of those in the talazoparib arm had triple-negative breast cancer versus 41.7% in the chemotherapy arm. (ahdbonline.com)
20182
- I would suggest that it is," stated Mikel Ross, MSN, RN, AGNP-BC , of the Breast Medicine Service, Memorial Sloan Kettering Cancer Center (MSK), New York, at the 2018 Lynn Sage Breast Cancer Symposium hosted by the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago. (ascopost.com)
- In 2018, the US Food and Drug Administration (FDA) expanded the indications for the first poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (Lynparza), to become the first PARP inhibitor approved for the treatment of women with advanced breast cancer and a deleterious or suspected deleterious germline BRCA mutation, as detected by BRAC Analysis CDx test. (ahdbonline.com)
Sentinel lymph node2
- And, there is a report that NC enabled sentinel lymph node biopsy for patients who require axillary dissection during the initial evaluation [ 3 - 5 ]. (kjco.org)
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. (jamanetwork.com)
Ovarian2
- And our friends in ovarian cancer moved ahead a bit quicker. (medscape.com)
- Two human genes, BRCA1 and BRCA2 ( BRCA1 / 2 ), produce proteins that block the growth of cancer, such as breast or ovarian cancer. (ahdbonline.com)
Cardiac5
- Newswise - Toronto, ON - Results of a multi- centre , international, clinical trial co-led by Peter Munk Cardiac Centre (PMCC) cardiologist Dr. Dinesh Thavendiranathan point to the benefit of using a more sensitive test to detect heart function issues early , so cancer patients don't have to fight heart failure too. (newswise.com)
- A decline in ejection fraction occurred in one patient with a preexisting cardiac condition who also received anthracycline-based chemotherapy and trastuzumab. (researchwithrutgers.com)
- The aim of this study was to implement a deep learning framework to quantify excess cardiac risk from anthracycline chemotherapy in real-world care. (ed.ac.uk)
- At a median follow up of 8.2 years, 448 cardiac events & 559 breast cancer deaths occurred. (ed.ac.uk)
- Conclusions: Taking into account competing risks, there was no statistically increased rate of cardiac events in women treated with anthracycline compared with non-anthracycline chemotherapy or no chemotherapy. (ed.ac.uk)
Invasive breast1
- Data on new cases of invasive breast cancer diagnosed during 2005-2009 were obtained from population-based cancer registries affiliated with the NPCR and SEER programs, which combined cover all of the US population. (cdc.gov)
Curative1
- Palliative tion and chemotherapy changes the body and causes side-effects curative and palliative patients are presented separately Stages not reported! (web.app)
Median4
- Results: The cohort was comprised of 12 patients who underwent VMAT for bilateral RNI, with a median follow-up time of 14.5 months. (researchwithrutgers.com)
- No patients required medical intervention for pulmonary complaints despite a median bilateral V 5 approaching 100%, providing further evidence that V 5 is not predictive for complications. (researchwithrutgers.com)
- The median patient age was 54 and the median follow-up time was 79 months. (biomedcentral.com)
- Among 875 patients from the Phase 3 study, a total of 367 patients were enrolled in the extension study, with a median follow-up of 53 months. (biospace.com)
Lymph node6
- Generally, tumor size and axillary lymph node metastasis status are the most important prognostic factors for breast cancer patients. (kjco.org)
- Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. (jamanetwork.com)
- Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. (jamanetwork.com)
- In this study, we investigated the prognostic value of uPA and PAI-1 at the mRNA level in lymph node- and hormone receptor-positive breast cancer. (biomedcentral.com)
- The study included a retrospective series of 87 patients with hormone-receptor positive and axillary lymph node-positive breast cancer. (biomedcentral.com)
- Diagnosis is based on lymph node biopsy. (msdmanuals.com)
Diagnosis7
- Breast cancer incidence, stage at diagnosis, and mortality rates for 2005-2009 for women in the United States and for each state were calculated using United States Cancer Statistics (USCS) data. (cdc.gov)
- However, black women experience inequities in breast cancer screening, follow-up, and treatment after diagnosis, leading to greater mortality. (cdc.gov)
- The MIR represents the number of breast cancer deaths per 100 breast cancers diagnosed and is an indication of prognosis after diagnosis. (cdc.gov)
- We included 1449 patients with diagnosis of invasive primary breast cancer diagnosed at the MD Anderson Cancer Center between 1995 and 2007 who underwent neoadjuvant chemotherapy. (jcancer.org)
- Thus, up to 40% of cancer patients are anaemic at diagnosis, and the prevalence increases to almost 80% during radio- and/or chemotherapy ( 1 - 3 ). (iiarjournals.org)
- 1 - 5 ] Anxiety and depression-common psychological responses to the diagnosis of cancer, cancer treatment, and hospitalization-are highly correlated with insomnia. (cancer.gov)
- 2011). Considerable progress has been made in terms of breast cancer diagnosis and treatment in the last years. (justia.com)
Conclusions1
- Conclusions: VMAT appears to be a feasible and tolerable RT modality for patients with breast cancer who require bilateral comprehensive adjuvant RT with RNI to obtain excellent target coverage. (researchwithrutgers.com)
Epirubicin1
- Doctors prescribe epirubicin alongside other medications to treat breast cancer in people who have already had surgery to remove the tumor. (medicalnewstoday.com)
Bevacizumab2
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). (curehunter.com)
- Table 1 summarises the results from phase II trials utilizing bevacizumab in combination with chemotherapy, many of which are still preliminary. (biomedcentral.com)
Trastuzumab based2
- If the ejection fraction is less than 50 percent (low limit of normal), they are not eligible for trastuzumab based on current practice standards. (acc.org)
- For T1c, adjuvant trastuzumab-based chemotherapy is considered standard. (onclive.com)
Node-positive breast cancer2
- Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. (jamanetwork.com)
- Axillary dissection may be considered in cases of node-positive breast cancer. (medscape.com)
Concurrently1
- However, in patients who had received or were concurrently receiving anthracycline-based chemotherapy in addition to trastuzumab, the occurrence of heart damage was halved among those taking either the angiotensin converting enzyme inhibitor (ACE-inhibitor) lisinopril or beta blocker carvedilol, compared with placebo after two years of follow-up. (acc.org)
Aggressive1
- To date, there are no effective and well-tolerated cytostatics for the palliative treatment of patients who are not suitable for aggressive anthracycline-based chemotherapy. (spandidos-publications.com)
Incidence8
- Despite having lower incidence rates, black women had a 41% higher breast cancer death rate. (cdc.gov)
- Despite significant progress in breast cancer detection and treatment, black women experience higher death rates even though they have a lower incidence of breast cancer compared to white women. (cdc.gov)
- This report summarizes disparities in breast cancer incidence and mortality between white and black women in the United States, using data from USCS for 2005-2009. (cdc.gov)
- USCS includes mortality data from the National Vital Statistics System (NVSS) and incidence data from the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) program. (cdc.gov)
- Annual breast cancer incidence and mortality rates per 100,000 women were age-adjusted by the direct method to the 2000 U.S. standard population (19 age groups), and corresponding 95% confidence intervals (CIs) were calculated. (cdc.gov)
- The global incidence of breast cancer (BC) is rising, especially in low- and middle-income countries. (karger.com)
- BC has the highest incidence rate of all cancers in women worldwide (1.67 million) and accounts for over 500,000 deaths annually [ 2 ]. (karger.com)
- The incidence of anaemia increases with the progression of the disease and the age of patients. (iiarjournals.org)
Dose7
- Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. (drugs.com)
- Hepatic Impairment: A lower starting dose is recommended for patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment. (drugs.com)
- Renal Impairment: A lower starting dose is recommended for patients with moderate (CLcr 30-49 mL/min) or severe (CLcr 15-29 mL/min) renal impairment. (drugs.com)
- Average cumulative dose was also calculated for early (cycles 1-3) and late (cycles 4-6) chemotherapy. (jnccn.org)
- 2005) In children with acute lymphoblastic leukemia who received high-dose methotrexate, oxidative damage to proteins as well as other factors was related to toxic side effects. (pinestreetfoundation.org)
- Patients who vomit or miss a dose should not take an additional dose, but should take the next prescribed dose at the usual time. (ahdbonline.com)
- WOCBP in both arms should use highly effective birth control measures, during the study treatment period and for at least 6 months after the last dose of chemotherapy or date of surgery (except for women receiving chemotherapy with ifosfamide who should continue contraception until 1 year after last day of treatment). (who.int)